Ann: ACW XanaCIDD phase 2a trial topline results, page-21

This is the problem with trying to develop drugs for depression.

There is no single, universally accepted binary objective chemical measurement for diagnosing depression. Depression is a complex mental health condition with a variety of contributing factors, biological, psychological, and environmental. Thus clinical studies in this field are extremely difficult, as other have said here the safety profile is the positive take away from this trial.

Shareholders still have another bun in the oven so not the end of the world.

Take it easy today folks.